Cipla net profit rises 7 percent to Rs 808 crore in Q3

Written by Ruchika Sharma Published On 2023-01-28T10:15:45+05:30 | Updated On 28 Jan 2023 10:15 AM IST

Cipla net profit rises 7 percent to Rs 808 crore in Q3

New Delhi: Drug major Cipla on Wednesday reported a 7 percent increase in its consolidated net profit to Rs 808 crore for the third quarter ended December 2022, aided by robust sales.

The Mumbai-based drug maker had reported a net profit of Rs 757 crore for the October-December period of the last fiscal.

Its total revenue from operations rose to Rs 5,810 crore for the third quarter compared to Rs 5,479 in the year-ago period, Cipla said in a regulatory filing.

For the nine months ended December 31, 2022, the company reported a net profit of Rs 2,311 crore against Rs 2,176 crore in the same period last fiscal.

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

The company specializes in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla's 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to 86 markets.

Read also: Cipla UK subsidiary to infuse EUR 15 million in Ethris

ciplacipla newsnet profitfinancial resultsQ3 profit

Source : with inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751